menu
    • menu
    [{"orgOrder":0,"company":"Roxall Medicina Espa\u00f1a","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus","moa":"Allergen cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I","graph3":"Roxall Medicina Espa\u00f1a","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roxall Medicina Espa\u00f1a \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Roxall Medicina Espa\u00f1a \/ Undisclosed"},{"orgOrder":0,"company":"Inmunotek","sponsor":"BioClever 2005 | NTS Hub S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmunotek \/ BioClever 2005 | NTS Hub S.L.","highestDevelopmentStatusID":"10","companyTruncated":"Inmunotek \/ BioClever 2005 | NTS Hub S.L."},{"orgOrder":0,"company":"Inmunotek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase II","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmunotek \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inmunotek \/ Undisclosed"},{"orgOrder":0,"company":"Inmunotek","sponsor":"BioClever 2005 | NTS Hub S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SPAIN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Dermatophagoides Pteronyssinus","moa":"Allergen cell","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inmunotek \/ BioClever 2005 | NTS Hub S.L.","highestDevelopmentStatusID":"10","companyTruncated":"Inmunotek \/ BioClever 2005 | NTS Hub S.L."}]

    Find Clinical Drug Pipeline Developments & Deals for Dermatophagoides Pteronyssinus

    Menu

    Dermatophagoides Pteronyssinus

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Inmunotek

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Inmunotek

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dermatophagoides Pteronyssinus

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : BioClever 2005 | NTS Hub S.L.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivit...

                            Details : Dermatophagoides Pteronyssinus is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dust Mite Allergy.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 02, 2022

                            Lead Product(s) : Dermatophagoides Pteronyssinus

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : BioClever 2005 | NTS Hub S.L.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Inmunotek

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Inmunotek

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dermatophagoides Pteronyssinus

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase III

                            Sponsor : BioClever 2005 | NTS Hub S.L.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis

                            Details : Dermatophagoides Pteronyssinus is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rhinoconjunctivitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 06, 2021

                            Lead Product(s) : Dermatophagoides Pteronyssinus

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase III

                            Sponsor : BioClever 2005 | NTS Hub S.L.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Roxall Medicina España

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Roxall Medicina España

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dermatophagoides Pteronyssinus

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Allergic Rhinoconjunctiv...

                            Details : Dermatophagoides Pteronyssinus is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rhinoconjunctivitis, Allergic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 29, 2016

                            Lead Product(s) : Dermatophagoides Pteronyssinus

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Inmunotek

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Inmunotek

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dermatophagoides Pteronyssinus

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy

                            Details : Dermatophagoides Pteronyssinus is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rhinitis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 25, 2016

                            Lead Product(s) : Dermatophagoides Pteronyssinus

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth